BPC-157: what three decades of research actually show

A peptide that came out of the stomach

Stomach juice is built to destroy proteins. Acid unfolds them and pepsin cuts them into pieces. So it is a strange place to go looking for a healing molecule, and a stranger one to find a peptide that reportedly survives there ^[11].

That is the origin story of BPC-157, short for "Body Protection Compound 157". Over three decades it has moved from a Croatian pharmacology lab to athletes, anti-doping lists and, in 2026, a vote at the US Food and Drug Administration ^[10,15]. Its reputation rests on a large body of rat studies in which injured tendons, muscles and guts appeared to heal faster.

The problem is the gap between that reputation and the human data. This article walks through both, and through the reasons regulators remain cautious.

Origin: a Zagreb lab and a 40,000-dalton protein

In 1993, Sikirić and colleagues at the University of Zagreb's Department of Pharmacology described "a new gastric juice peptide", a protein of about 40,000 daltons they named BPC ^[1]. They proposed that the stomach, under stress, launches a counter-response that protects other organs, an idea they called "organoprotection" ^[1].

From that protein they characterised a 15-amino-acid fragment, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, which they believed carried its activity ^[1]. That fragment is BPC-157. The material used in research today is made by chemical peptide synthesis, not extracted from stomachs ^[11].

A Croatian drug company, Pliva, then developed the fragment as PL 14736, an enema for inflammatory bowel disease ^[2,11]. An early laboratory report found that the peptide resisted breakdown in human gastric juice ^[11].

Of 235 PubMed records on BPC-157, 175 list the same Zagreb scientist as a co-author ^[14].

That concentration matters. Independent replication is how science separates a real effect from one lab's particular methods, and for BPC-157 it is still limited. Much of the independent laboratory work comes from a group at Chang Gung University in Taiwan ^[3,6].

How a stomach peptide might talk to blood vessels

FDA reviewers describe the mechanisms of action of BPC-157 as poorly understood ^[11]. What exists are clues from cell and animal studies.

The clearest clue concerns blood vessels. In human endothelial cells, BPC-157 increased levels of VEGFR2, a receptor for one of the body's main blood-vessel growth signals, and switched on its downstream Akt-eNOS pathway ^[6]. In rats with blocked leg arteries, treated animals recovered blood flow faster and grew more small vessels ^[6].

The second clue concerns cell movement. In tendon cells, BPC-157 did not make cells divide faster. Instead it helped them survive oxidative stress and made them migrate and spread more, through a signalling pair called FAK and paxillin ^[3].

A useful picture is a foreman on a building site rather than a bricklayer. BPC-157 does not seem to build tissue itself. In these models it appears to call in supply routes (new vessels) and get workers (fibroblasts) moving toward the damage.

One puzzle remains. In rats and dogs, injected BPC-157 is cleared from the blood within minutes, with half-lives of about 5 to 15 minutes ^[11]. How such a short-lived peptide produces effects lasting days or weeks is not explained.

What the research shows

Tendon

In the founding tendon study, rats with a cut Achilles tendon received daily injections of BPC-157 or saline for up to 14 days ^[2]. Treated tendons withstood more load before failing, the animals walked better, and the tissue showed more fibroblasts and collagen ^[2]. The Taiwanese group later found that the peptide sped up the outgrowth of tendon cells from tissue explants ^[3].

Ligament

In rats with a cut medial collateral ligament of the knee, BPC-157 improved functional, biomechanical and microscopic healing over 90 days ^[4]. It appeared to work whether given by injection, in drinking water or as a cream on the wound ^[4]. Oral and topical activity would be unusual for a peptide, and we found no independent replication of it.

Muscle

After complete cutting of the quadriceps muscle in rats, daily BPC-157 improved the load the healed muscle could bear, walking function and the reconnection of muscle fibres across a 72-day study ^[5].

Gut

This is where the work began. In rodent models, the Zagreb group reported protection against stomach lesions caused by NSAID painkillers and against liver injury, and faster healing of surgically created colon fistulas ^[11]. This gut work is the background to the peptide's development as an inflammatory bowel disease drug ^[2,11].

Blood vessels

Beyond the leg-ischaemia model above, BPC-157 increased vessel density in the chick-embryo membrane assay and tube formation by endothelial cells in culture ^[6].

In humans

The human record is short enough to list in full.

The colitis trial is the only randomised efficacy trial of BPC-157 with any published results. FDA reviewers concluded that, because it exists only as a meeting abstract with key details missing, it cannot support efficacy or safety ^[11]. An oral phase 1 trial registered in Mexico in 2015 has never posted results ^[11].

The three recent studies share the same first author and were run in private clinical practice ^[7-9]. In the knee study, patients were asked by phone, months later, to rate their pain before and after injection ^[7]. The two intravenous-study participants had received the peptide before the trial began ^[9]. A systematic review published in October 2026 rated all three as poor quality and the overall certainty of evidence as very low ^[10].

What we don't know yet

Whether it works in people. No completed, published, placebo-controlled trial shows benefit for any condition ^[10,11]. Animal healing models often fail to predict human results.

Whether the animal results replicate. With about three-quarters of the literature from one group ^[14], independent replication of the tendon, ligament and muscle findings is the most important missing piece.

How it is handled by the human body. There are no human pharmacokinetic data for oral, injected or nasal use ^[11].

Long-term safety. No study has followed people for months or years ^[11]. FDA's adverse-event database holds three reports linked to injected BPC-157 products, including injection-site swelling, shortness of breath, and skin darkening with a product that also contained TB-500, but none proves cause ^[11].

Immune reactions and purity. FDA's main concern is that injected or nasal peptides can provoke immune responses, especially if they clump together or carry synthesis impurities, and that no one has studied this for BPC-157 ^[11,12]. Product quality is part of the safety question, not separate from it.

Regulatory status

• Approval: BPC-157 has no regulatory approval for human use in any country, including the US and the EU ^[10], and it is not part of any FDA-approved drug ^[11].
• WADA: Named under class S0 (non-approved substances) from the 2022 Prohibited List onward and still listed in 2026. It is prohibited in and out of competition ^[13].
• FDA, 2023: On 29 September 2023, FDA placed BPC-157 in "Category 2", substances that may pose significant safety risks in compounding. Its reasons were possible immunogenicity, impurity and characterisation problems, and little or no safety information for the proposed routes ^[12].
• FDA, 2026: After the nominators withdrew their requests, FDA moved BPC-157 to a "nominated but withdrawn" list by April 2026 ^[12]. It still reviewed the peptide for ulcerative colitis and recommended against adding it to the compounding list ^[11]. On 23 July 2026 its Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favour ^[15]. The vote is advisory, and any listing would require FDA rulemaking ^[15].

In the lab: handling and storage

BPC-157 is supplied as a lyophilised (freeze-dried) powder, which is the most stable form for a peptide. Common laboratory practice is long-term storage at −20 °C, with 2-8 °C acceptable for short periods, and protection from light and moisture. Once reconstituted, solutions are usually kept refrigerated and used within a short window, and repeated freeze-thaw cycles are avoided. FDA notes that formulation and storage conditions can drive the formation of peptide impurities ^[11], which is one reason to check the certificate of analysis for each lot. Our guide to storing research peptides covers this in more detail.

FAQ